Used in targeted cancer therapy, particularly for triple-negative breast cancer and other solid tumors expressing Trop2 antigen. The antibody binds to Trop2 on cancer cells, enabling selective delivery of the cytotoxic agent MMAE. Upon internalization, MMAE disrupts microtubule networks, leading to cell cycle arrest and apoptosis. This conjugate enhances tumor cell killing while minimizing damage to healthy tissues, offering a targeted approach in antibody-drug conjugate (ADC) treatments. It serves as a reference standard in development and quality control of biosimilars and novel ADCs.